泽璟制药-U
(688266)
| 流通市值：232.94亿 | | | 总市值：232.94亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,134,543,569.13 | 2,320,274,300.16 | 1,989,124,501.13 | 2,109,640,875.32 |
| 应收票据及应收账款 | 132,638,815.48 | 130,880,379.36 | 112,023,076.65 | 101,139,998.16 |
| 应收账款 | 132,638,815.48 | 130,880,379.36 | 112,023,076.65 | 101,139,998.16 |
| 预付款项 | 56,167,118.21 | 44,908,331.29 | 51,902,096.75 | 46,250,585.38 |
| 其他应收款合计 | 9,531,046.62 | 9,359,639.62 | 10,227,345.34 | 10,894,988.6 |
| 存货 | 160,289,459.88 | 141,123,246.36 | 130,430,627.8 | 110,852,343.86 |
| 其他流动资产 | 3,004,080.8 | 2,962,349.27 | 3,514,558.6 | 4,538,472.24 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,565,243,592.54 | 2,705,741,942.97 | 2,722,994,152.5 | 2,520,336,094.4 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 5,987,768.53 | 5,987,768.53 | 5,987,768.53 | 5,987,768.53 |
| 固定资产 | 195,613,234.99 | 107,293,300.68 | 95,022,401.79 | 98,289,417.59 |
| 在建工程 | 74,906,160.45 | 146,906,382.55 | 154,687,504.89 | 135,826,970.65 |
| 使用权资产 | 37,045,286.83 | 39,645,470.38 | 42,396,966.14 | 37,088,669.86 |
| 无形资产 | 54,142,400.64 | 59,515,174.85 | 64,377,650.12 | 69,269,782.52 |
| 长期待摊费用 | 27,036,524.79 | 28,748,014.81 | 15,222,027.66 | 16,390,550.81 |
| 其他非流动资产 | 7,172,941.23 | 5,824,970.31 | 4,059,481.31 | 4,017,570.95 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 401,904,317.46 | 393,921,082.11 | 381,753,800.44 | 366,870,730.91 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,967,147,910 | 3,099,663,025.08 | 3,104,747,952.94 | 2,887,206,825.31 |
| 流动负债: | | | | |
| 短期借款 | 882,215,559.32 | 914,209,554.82 | 953,387,099.71 | 795,164,810.85 |
| 应付票据及应付账款 | 152,642,391.77 | 128,855,118.06 | 122,207,712.81 | 137,734,514.83 |
| 其中：应付票据 | 4,498,500 | 4,498,500 | - | - |
| 应付账款 | 148,143,891.77 | 124,356,618.06 | 122,207,712.81 | 137,734,514.83 |
| 预收款项 | 38,226.3 | 61,162.08 | 84,097.86 | 107,033.64 |
| 应付职工薪酬 | 56,082,939.06 | 49,563,037.3 | 53,796,138.5 | 65,250,987.29 |
| 应交税费 | 34,369,359.77 | 36,564,979.79 | 29,945,038.58 | 33,015,290.95 |
| 其他应付款合计 | 177,017,708.57 | 21,790,773.12 | 32,242,210.44 | 30,134,274.18 |
| 一年内到期的非流动负债 | 11,310,603.39 | 13,174,496.86 | 13,916,453.55 | 63,732,890.83 |
| 其他流动负债 | - | 4,913,948.01 | 2,611,074.14 | 10,041,434.3 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,313,676,788.18 | 1,169,133,070.04 | 1,208,189,825.59 | 1,135,181,236.87 |
| 非流动负债: | | | | |
| 租赁负债 | 29,539,566.44 | 29,180,256.79 | 31,525,903.95 | 29,455,850.25 |
| 递延收益 | 12,700,103.68 | 14,015,395.15 | 10,430,686.62 | 11,545,978.09 |
| 递延所得税负债 | 6,538,660.02 | 7,647,583.85 | 8,606,520.01 | 9,582,937.93 |
| 其他非流动负债 | 301,886,793.43 | 311,320,755.67 | 245,283,019.8 | 56,603,773.8 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 350,665,123.57 | 362,163,991.46 | 295,846,130.38 | 107,188,540.07 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,664,341,911.75 | 1,531,297,061.5 | 1,504,035,955.97 | 1,242,369,776.94 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 264,708,186 | 264,708,186 | 264,708,186 | 264,708,186 |
| 资本公积 | 3,097,275,094.65 | 3,353,448,970.1 | 3,353,266,259.9 | 3,353,006,007.66 |
| 其他综合收益 | 18,218,907.37 | -5,664,888.11 | -5,869,772.59 | -5,949,767.5 |
| 未分配利润 | -2,076,814,691.77 | -2,045,447,779.47 | -2,018,411,091.49 | -1,978,911,708.48 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,303,387,496.25 | 1,567,044,488.52 | 1,593,693,581.82 | 1,632,852,717.68 |
| 少数股东权益 | -581,498 | 1,321,475.06 | 7,018,415.15 | 11,984,330.69 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,302,805,998.25 | 1,568,365,963.58 | 1,600,711,996.97 | 1,644,837,048.37 |
| 负债和股东权益合计 | 2,967,147,910 | 3,099,663,025.08 | 3,104,747,952.94 | 2,887,206,825.31 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |